Last reviewed 2026-04-20 · How we verify

Succitimal (PHENSUXIMIDE)

FDA-approved approved Small molecule Quality 30/100

Succitimal (generic name: PHENSUXIMIDE) is a phensuximide drug. It is currently FDA-approved (first approved 1982) for Absence seizure, Epilepsy.

Succinimide (PHENSUXIMIDE) is a small molecule drug that targets voltage-gated T-type calcium channels. It is classified as a phensuximide and is used to treat absence seizures and epilepsy. Although it is off-patent, there are currently no generic manufacturers. As a result, its commercial status is uncertain. Key safety considerations are not well-documented due to a lack of information on its half-life and bioavailability.

At a glance

Generic name	PHENSUXIMIDE
Drug class	phensuximide
Target	Voltage-gated T-type calcium channel
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	FDA-approved
First approval	1982

Approved indications

Absence seizure
Epilepsy

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Succitimal CI brief — competitive landscape report
Succitimal updates RSS · CI watch RSS

Frequently asked questions about Succitimal

What is Succitimal?

Succitimal (PHENSUXIMIDE) is a phensuximide drug, indicated for Absence seizure, Epilepsy.

What is Succitimal used for?

Succitimal is indicated for Absence seizure, Epilepsy.

What is the generic name of Succitimal?

PHENSUXIMIDE is the generic (nonproprietary) name of Succitimal.

What drug class is Succitimal in?

Succitimal belongs to the phensuximide class. See all phensuximide drugs at /class/phensuximide.

When was Succitimal approved?

Succitimal was first approved on 1982.

What development phase is Succitimal in?

Succitimal is FDA-approved (marketed).

What does Succitimal target?

Succitimal targets Voltage-gated T-type calcium channel and is a phensuximide.

Drug class: All phensuximide drugs
Target: All drugs targeting Voltage-gated T-type calcium channel
Therapeutic area: All drugs in Neuroscience
Indication: Drugs for Absence seizure
Indication: Drugs for Epilepsy

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing